JP2018504122A5 - - Google Patents

Download PDF

Info

Publication number
JP2018504122A5
JP2018504122A5 JP2017539018A JP2017539018A JP2018504122A5 JP 2018504122 A5 JP2018504122 A5 JP 2018504122A5 JP 2017539018 A JP2017539018 A JP 2017539018A JP 2017539018 A JP2017539018 A JP 2017539018A JP 2018504122 A5 JP2018504122 A5 JP 2018504122A5
Authority
JP
Japan
Prior art keywords
ifn
item
cells
inflammation
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017539018A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504122A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/014942 external-priority patent/WO2016123117A1/en
Publication of JP2018504122A publication Critical patent/JP2018504122A/ja
Publication of JP2018504122A5 publication Critical patent/JP2018504122A5/ja
Priority to JP2020201293A priority Critical patent/JP7304844B2/ja
Priority to JP2023025696A priority patent/JP2023062155A/ja
Withdrawn legal-status Critical Current

Links

JP2017539018A 2015-01-26 2016-01-26 免疫調節特性が増加した細胞ならびにその使用および製造のための方法 Withdrawn JP2018504122A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2020201293A JP7304844B2 (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2023025696A JP2023062155A (ja) 2015-01-26 2023-02-22 免疫調節特性が増加した細胞ならびにその使用および製造のための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562107517P 2015-01-26 2015-01-26
US62/107,517 2015-01-26
US201562112653P 2015-02-06 2015-02-06
US62/112,653 2015-02-06
PCT/US2016/014942 WO2016123117A1 (en) 2015-01-26 2016-01-26 Cells with increased immuno-regulatory properties and methods for their use and manufacture

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020201293A Division JP7304844B2 (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2020201294A Division JP2021050220A (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法

Publications (2)

Publication Number Publication Date
JP2018504122A JP2018504122A (ja) 2018-02-15
JP2018504122A5 true JP2018504122A5 (https=) 2019-03-07

Family

ID=56544240

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2017539018A Withdrawn JP2018504122A (ja) 2015-01-26 2016-01-26 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2020201293A Active JP7304844B2 (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2020201294A Pending JP2021050220A (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2023010327A Pending JP2023052658A (ja) 2015-01-26 2023-01-26 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2023025696A Pending JP2023062155A (ja) 2015-01-26 2023-02-22 免疫調節特性が増加した細胞ならびにその使用および製造のための方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020201293A Active JP7304844B2 (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2020201294A Pending JP2021050220A (ja) 2015-01-26 2020-12-03 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2023010327A Pending JP2023052658A (ja) 2015-01-26 2023-01-26 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP2023025696A Pending JP2023062155A (ja) 2015-01-26 2023-02-22 免疫調節特性が増加した細胞ならびにその使用および製造のための方法

Country Status (7)

Country Link
US (6) US20180112180A1 (https=)
EP (2) EP3250682A4 (https=)
JP (5) JP2018504122A (https=)
CN (2) CN112481211B (https=)
AU (3) AU2016211688A1 (https=)
CA (1) CA2974903A1 (https=)
WO (1) WO2016123117A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016211671B2 (en) 2015-01-26 2022-05-26 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
RU2018106515A (ru) 2015-07-21 2019-08-21 Зе Чилдрен'С Медикал Сентер Корпорейшн Pd-l1-экспрессирующие гемопоэтические стволовые клетки и применения
JP6928604B2 (ja) 2015-11-04 2021-09-01 フェイト セラピューティクス，インコーポレイテッド 万能性細胞のゲノム改変
CA3003152A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CA3010236A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3405568A4 (en) 2016-01-20 2019-12-04 Fate Therapeutics, Inc. COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
US9918994B2 (en) 2016-03-04 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
WO2018106595A1 (en) 2016-12-05 2018-06-14 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
WO2018227138A1 (en) 2017-06-09 2018-12-13 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for preventing or treating muscle conditions
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
CN107714717A (zh) * 2017-10-11 2018-02-23 刘志强 聚肌胞苷酸在制备治疗或预防结肠炎的药物中的应用
EP3752598B1 (en) * 2018-02-16 2022-11-02 NextCell Pharma AB Allogeneic composition
EP3863650A4 (en) * 2018-10-10 2022-09-14 North Carolina State University PRESENTATION BLISTERS OF PD-L1 TO REVERSE NEW ONSET OF TYPE 1 DIABETES
WO2020077204A1 (en) * 2018-10-12 2020-04-16 Salk Institute For Biological Studies Cells, islets, and organoids that evade immune detection and autoimmunity, methods of production and use thereof
CN109706180A (zh) * 2019-01-11 2019-05-03 杭州荣泽生物科技有限公司 一种脐带间充质干细胞过表达ido增强免疫抑制的方法及应用
CN118240767A (zh) * 2019-02-09 2024-06-25 美国卫生和人力服务部 作为减少或预防转移、治疗自身免疫和炎性病症以及重新平衡免疫环境和失调的小生境的平台的基因修饰的hspc及间充质细胞
AU2020311877B2 (en) * 2019-07-05 2024-01-04 Case Western Reserve University Priming media and methods for stem cell culture and therapy
WO2021167770A1 (en) * 2020-02-18 2021-08-26 Octagon Therapeutics, Inc. Immune cell modulators
WO2021263097A2 (en) * 2020-06-26 2021-12-30 The Children's Medical Center Corporation Methods and compositions for treating multiple sclerosis
CN116322317B (zh) * 2020-07-08 2025-12-12 杰克逊实验室 表达人hla-a201限制基因的转基因小鼠模型
JP7840930B2 (ja) 2021-03-24 2026-04-06 キヤノン株式会社 虚像光学系、それを備える虚像表示装置及び車載システム
KR20220162394A (ko) * 2021-06-01 2022-12-08 에스씨엠생명과학 주식회사 기능강화 줄기세포 및 조절 t 세포를 포함하는 아토피 피부염 예방 또는 치료용 병용투여 조성물
WO2025043075A1 (en) * 2023-08-24 2025-02-27 The Johns Hopkins University Methods of treating myocardial infarction, ischemia, and ischemia reperfusion injury
WO2025199431A1 (en) * 2024-03-22 2025-09-25 Colorado State University Research Foundation Innate immune pathway activated mesenchymal stromal cells for treatment of musculoskeletal disorders or conditions

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
IL141120A0 (en) 2000-01-31 2002-02-10 Pfizer Prod Inc Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20060292618A1 (en) * 2002-04-12 2006-12-28 Mellor Andrew L Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
EP1501918A4 (en) * 2002-04-12 2006-03-29 Med College Georgia Res Inst ANTIGEN PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS TO INCREASE OR REDUCE IMMUNO TOLERANCE
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
WO2005040391A1 (en) * 2003-10-27 2005-05-06 Murdoch Childrens Research Institute Compositions and methods for differentiating stem cells
US7951592B2 (en) 2003-11-10 2011-05-31 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
DE102005062741A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Fluorene und Carbazole als Liganden des EP2 Rezeptors
US7871605B2 (en) * 2006-11-03 2011-01-18 Aastrom Bioscience, Inc. Mixed cell populations for tissue repair and separation technique for cell processing
EP2626416A3 (en) 2007-04-07 2013-12-18 The Whitehead Institute for Biomedical Research Reprogramming of somatic cells
EP2578677A1 (en) * 2007-08-09 2013-04-10 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
AU2008297011B2 (en) 2007-08-31 2014-06-12 Whitehead Institute For Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
SG188904A1 (en) 2008-03-17 2013-04-30 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
CN102575227A (zh) * 2008-10-08 2012-07-11 英特瑞克斯顿股份有限公司 表达多种免疫调节剂的工程改造细胞及其应用
PT3031907T (pt) 2008-11-06 2021-01-28 Univ Indiana Res & Tech Corp Materiais e métodos para melhorar procedimentos de enxerto de células estaminais hematopoiéticas
BRPI0922572A2 (pt) 2008-12-17 2019-09-24 Scripps Research Inst método para cultivar células pluripotentes, cultura de células de mamífero pluripotentes, meio de cultura de célula, célula animal pluripotente isolada, e, método para aumentar a pluripotência de uma célula de mamífero.
EP2408444A4 (en) 2009-03-19 2012-09-26 Fate Therapeutics Inc COMPOSITIONS WITH CYCLIC AMP AMPLIFIERS AND / OR EP LIGANDS, AND METHOD FOR THEIR PRODUCTION AND USE
ES2455544T5 (es) * 2009-07-24 2017-08-16 Immune Design Corp Vectores de lentivirus pseudotipificados con una glucoproteína de envoltura de virus sindbis
AU2010306627B2 (en) 2009-10-16 2014-07-17 The Scripps Research Institute Induction of pluripotent cells
WO2011060218A1 (en) * 2009-11-13 2011-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulated programmed death ligand-1
CN102471753B (zh) * 2009-12-08 2014-10-22 伊利诺伊大学理事会 干细胞免疫调节应用方法和设备
CA2794196A1 (en) * 2010-03-23 2011-09-29 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
BR112012024565B1 (pt) * 2010-03-26 2022-02-08 Trustees Of Dartmouth College Proteína de fusão vista imunossupressora multimérica isolada ou recombinante e composição
EP2603227B1 (en) * 2010-08-12 2017-10-04 Fate Therapeutics, Inc. Improved hematopoietic stem and progenitor cell therapy
WO2013040552A2 (en) * 2011-09-16 2013-03-21 Georgia Health Sciences University Methods of promoting immune tolerance
EP3785767A1 (en) * 2011-12-02 2021-03-03 Fate Therapeutics, Inc. Enhanced stem cell composition
US20150139994A1 (en) * 2013-11-12 2015-05-21 The Regents Of The University Of California Compositions and methods for preventing allogeneic immune rejection
RU2018106515A (ru) * 2015-07-21 2019-08-21 Зе Чилдрен'С Медикал Сентер Корпорейшн Pd-l1-экспрессирующие гемопоэтические стволовые клетки и применения

Similar Documents

Publication Publication Date Title
JP2018504122A5 (https=)
JP2021050220A5 (https=)
JP7304844B2 (ja) 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
Wang et al. Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells
JP2017136094A5 (https=)
JP6396544B2 (ja) エクトインの治療的使用
KR20150053982A (ko) 올레아놀산의 ｃ１７―헤테로아릴 유도체 및 그의 사용 방법
US8829024B2 (en) Combination steroid and glucocorticoid receptor antagonist therapy
JP2023520233A (ja) 間葉系統前駆細胞又は幹細胞を使用する過炎症の治療方法
JP2024147655A (ja) 内皮機能不全及び炎症の疾患の治療
Etra et al. Remestemcel-L-rknd (Ryoncil): the first approved cellular therapy for steroid-refractory acute GVHD
JP2019529472A5 (https=)
JP2019055913A (ja) ビタミンｄ活性を有するリトコール酸誘導体
JPWO2021119522A5 (https=)
KR102596422B1 (ko) 줄기세포의 염증부위로의 이동능 강화방법
US20040248863A1 (en) Combination of a ppar-alpha ligand and glucocorticoid for the treatment or prevention of inflamation
EP4346816A2 (en) Compounds for use in a method for treating an autoimmune and inflammatory disease
JPWO2023040879A5 (https=)
Adcock et al. C13 Corticosteroids
HK1210209B (en) Treatment of diseases of endothelial dysfunction and inflammation